Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.56 |
| ▸ | MEN1 | O00255 | 3/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 3/20 | 0.53 |
| ▸ | NPC1 | O15118 | 3/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.45 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7073296 | 1.00 | KMT2A (0.56) | KMT2AMEN1ALDH1A1L3MBTL1RAB9A | |
| SCHEMBL7075789 | 0.95 | KMT2A (0.52) | KMT2AMEN1ALDH1A1L3MBTL1RAB9A | |
| SCHEMBL7075794 | 0.95 | KMT2A (0.52) | KMT2AMEN1ALDH1A1L3MBTL1RAB9A | |
| SCHEMBL27860174 | 0.92 | KMT2A (0.56) | KMT2AMEN1ALDH1A1L3MBTL1RAB9A | |
| SCHEMBL1829847 | 0.82 | HDAC2 (0.53) | KMT2AMEN1ALDH1A1L3MBTL1RAB9A | |
| SCHEMBL12247420 | 0.82 | HDAC2 (0.53) | KMT2AMEN1ALDH1A1L3MBTL1RAB9A | |
| SCHEMBL10666923 | 0.81 | SMN1; SMN2 (0.42) | KMT2AMEN1ALDH1A1SMN1; SMN2TSHR | |
| SCHEMBL4744831 | 0.80 | SMN1; SMN2 (0.67) | KMT2AMEN1ALDH1A1L3MBTL1RAB9A | |
| SCHEMBL13588433 | 0.79 | SMN1; SMN2 (0.59) | KMT2AMEN1ALDH1A1L3MBTL1RAB9A | |
| SCHEMBL7072991 | 0.78 | KMT2A (0.67) | KMT2AMEN1ALDH1A1RAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030120088-A1 | Optically active azetidincarboxamide-coordinated transition metal complexes | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2003-06-26 | — | — | US | disclosed |
| EP-1319660-A1 | Optically active azetidincarboxamide-coordinated transition metal complexes as catalysts in asymmetric reduction | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2003-06-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030120088-A1 | Optically active azetidincarboxamide-coordinated transition metal complexes | AAAS, AP1M1, AP2A1 | KMT2A 1593/4885MEN1 398/4885ALDH1A1 1300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.